Chimeric Therapeutics Limited · ASX:CHM
Chimeric Therapeutics — Investor Presentation (October 2023)
32 slides from Chimeric Therapeutics's investor presentation, Oct 25, 2023
Slide 1: Bringing the Promise of Cell Therapy to Life: Entitlement Offer Presentation
BRINGING THE For personal use only PROMISE OF CELL THERAPY TO LIFE Entitlement Offer Presentation October 23
Slide 2: Disclaimer
Disclaimer The information in this presentation does not constitute personal investment advice. The presentation is are not as favourable as we anticipate; the risk that our clinical trials will be more costly than not intended to be comprehensive or provide all information required by investors to
Slide 3: Positive Phase 1 results, advancing clinical development, capital raise
2 CLINICAL TRIALS WITH ADVANCING CLINICAL POSITIVE PHASE 1 RESULTS DEVELOPMENT • Positive CHM 1101 Phase 1A data in • Innovative cell therapy portfolio with 3 recurrent brain cancer novel technology platforms For personal use only • Positive CHM 0201 Phase 1A data in • 4 ongoing clinical trials in s
Slide 4: Capital Raising Overview
CAPITAL RAISING OVERVIEW CHIMERIC IS RAISING UP TO A$10M VIA A NON-RENOUNCEABLE ENTITLEMENT OFFER For personal use only A 2 for 3 non-renounceable entitlement offer of new shares to existing shareholders to raise up to A$10m Offer Structure Record date to identify shareholders entitlement: 7pm (
Slide 5: Use of Funds
USE OF FUNDS Use of Funds Anticipated Clinical Deliverables to October 2024 For personal use only Rights Issue $10M CLTX CAR T CLTX CAR T • Chimeric Phase 1B Clinical Trial in Glioblastoma $6.2M • Complete Phase 1B Dose Confirmation • Initiate Phase 1B Dose Expansion CDH17 CAR T CDH17 CAR T • Chimer
Slide 6: Offer Timetable
OFFER TIMETABLE For personal use only Indicative capital raising timetable1 Date Announcement of non-renounceable entitlement offer Wednesday, 25 October 2023 Record date for Entitlement Offer Monday, 30 October 2023 Entitlement Offer Opens Thursday, 2 November 2023 Entitlement Offer Closes Monday,
Slide 7: Corporate Profile
CHIMERIC THERAPEUTICS (ASX: CHM) CORPORATE PROFILE Market Information For personal use only Share Price (AUD) $0.041 CHM Market Information (Oct. 24, 2023) (3-month share price as of Oct. 24, 2023) 52 Week Range (AUD) $0.025- 0.95 Shares on Issue 534 M Market Cap (AUD) ~$21.9M (Oct. 24, 2023) Top 5
Slide 8: Value Proposition for Investors
VALUE PROPOSITION FOR INVESTORS For personal use only 1. 2. 3. ADVANCED, ADVANCING NAVIGATING UNDERVALUED DEVELOPMENT TO THE PORTFOLIO VALUE REALISATION CHALLENGES Chimeric’s pipeline and Chimeric’s assets are Chimeric is responding to today’s portfolio are highly entering Phase 1B, biotech environm
Slide 9: Advanced, Undervalued Portfolio
1. ADVANCED, UNDERVALUED PORTFOLIO Chimeric has an industry leading cell therapy portfolio with novel technology platforms in clinical stage development 3 Novel technology For personal use only platforms 2 Assets with positive clinical data 4 Ongoing clinical trials MDACC: MD Anderson Cancer Centre/
Slide 10: Value Realization Opportunity Focuses on Phase 1B
VALUE REALIZATION OPPORTUNITY FOCUSES ON PHASE 1B/ 2 CHIMERIC IS ADVANCING DEVELOPMENT TO BIG PHARMA’S FOCUS In today's market, big pharma M&A has shifted its focus from preclinical assets to assets that are clinically de-risked with Phase1A/B data For personal use only Chimeric currently has 3 ongo
Slide 11: Navigating the Challenges
3. NAVIGATING THE CHALLENGES To enable clinical advancement, Chimeric has responded to the challenges of todays market with program prioritization and cash preservation while creating value through business development For personal use only
Slide 12: Focus on Program Prioritization and Cash Preservation
3. NAVIGATING THE CHALLENGES FOCUS ON PROGRAM PRIORTIZATION AND CASH PRESERRVATION For personal use only PROGRAM CASH PRIORITIZATION PRESERVATION • Focus on advancing clinical • End to end cash programs management • De-prioritized discovery • Significant headcount programs reductions
Slide 13: Responding to Challenges of Today's Market with Business Development
RESPONDING TO THE CHALLENGES OF TODAYS MARKET WITH BUSINESS DEVELOPMENT ADVANCING For personal use only ACCELERATING THROUGH LEVERAGING COLLABORATION CHIMERIC’S EARLY KNOW-HOW OUT-LICENSING Institutional collaborations have enabled Chimeric to Utilizing Chimeric’s expertise and experience accelerate
Slide 14: Chimeric: Novel Platform Technologies
CHIMERIC: 3 NOVEL PLATFORM TECHNOLOGIES CHM 1101 CHM 2101 CHM 0201 For personal use only (CLTX CAR T) (CDH17 CAR T) (CORE NK) 2020 2021 2022 Potentially best in class NK cell platform First in class CLTX CAR T for brain First in class CDH17 CAR T for blood cancers 2022 and solid tumours cancer and o
Slide 15: Positive Phase 1A Clinical Data in Recurrent, Late-Stage Brain Cancer
POSITIVE PHASE 1A CLINICAL DATA IN RECURRENT, LATE-STAGE BRAIN CANCER For personal use only DISEASE SURVIVAL SAFETY CONTROL RATE ~10 months Generally, well tolerated 55% Median survival in patients that achieved disease control • No Dose Limiting 14+ months Toxicities Disease Control Rate (DCR) • No
Slide 16: How Is Glioblastoma (GBM) Treated Today?
HOW IS GLIOBLASTOMA (GBM) TREATED TODAY? TREATMENT BECOMES MORE CHALLENGING AS THE DISEASE PROGRESSES Treatment in front line is the standard of Treatment in subsequent lines of therapy becomes progressively more difficult with For personal use only care combination of surgery, radiation and temozol
Slide 17: CHM 1101 Phase 1A Patient Demographics
CHM 1101 PHASE 1A PATIENT DEMOGRAPHICS TREATING 4TH LINE PATIENTS For personal use only Median 57 years 46% Age Range 37-73 years Male 55% of patients received CHM 1101 as Sex Female 45% 4th line therapy Caucasian 73% Black 9% Race Asian 9% CHM 1101 Patients Hispanic 9% 0 18% 2nd Line 3rd Line 4th L
Slide 18: CHM 1101 Results in Context
CHM 1101 RESULTS IN CONTEXT 55% DISEASE CONTROL IN LATE LINE PATIENTS For personal use only CHM 1101 2nd Line 4th Line 2nd Line Treatment1 Treatment Treatment2 20% 55% 37% Disease Control1 Disease Control Disease Control2 CHM 1101 was studied in median 4th line patients and demonstrated a Disease Co
Slide 19: Survival Expectations for Patients with Recurrent GBM
SURVIVAL EXPECTATIONS FOR PATIENTS WITH RECURRENT GBM Therapy Line of Therapy Overall Survival For personal use only SURGERY 2nd Line1 5.75 months1 ~7 months TUMOUR TREATING FIELDS 3rd Line2 6.6 months2 survival APPROVED THERAPIES demonstrated from BEVACIZUMAB 2nd Line3 7.75 months3 first recurrence
Slide 20: CHM 1101 Phase 1A Survival
CHM 1101 PHASE 1A SURVIVAL ~10 MONTH SURVIVAL IN PATIENTS WHO ACHIEVED DISEASE CONTROL Overall Survival (Months) For personal use only Patient 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 A 14+ months B In two patients who C achieved disease control D 9.9 months E Median overall survival in F
Slide 21: Patients with Long Term (14+ Months) Survival
CHM 1101 PHASE 1A PATIENTS WITH LONG TERM (14+ MONTHS ) SURVIVAL For personal use only CHM 1101 Dose: 44 X 106 CHM 1101 Dose: 88 X 106 Line of Therapy: 3rd Line of Therapy: 4th OVERALL ONGOING SURVIVAL SURVIVAL 19 14.4+ months months 10 79 10 70 Infusions Days to Relapse Infusions Days to Relapse
Slide 22: CHM 1101 Phase 1A Safety
CHM 1101 PHASE 1A SAFETY A MANAGEABLE SAFETY PROFILE AT ALL DOSE LEVELS Grade 3 (serious) For personal use only non-hematological events were not considered treatment related: No Dose No Cytokine No Tumour • Cerebral Edema X3* Limiting Release Lysis • Adrenal Insufficiency* Toxicities Syndrome Syndr
Slide 23: CHM 1101 Next Steps
CHM 1101 NEXT STEPS ADVANCING IN PHASE 1B CLINICAL DEVELOPMENT For personal use only 2021 AUG 23 NOV 23 PHASE 1A CLINICAL TRIAL IN RECURRENT PHASE 1A COMPLETION PHASE 1A PRELIMINARY GLIOBLASTOMA OF DOSE ESCALATION DOSE ESCALATION DATA JUN 23 2024 PHASE 1B PHASE 1B DOSE CONFIRMATION DOSE EXPA
Slide 24: CHM 2101 (CDH17 CAR T): Potent In Vivo Efficacy
CHM 2101 (CDH17 CAR T) POTENT IN VIVO EFFICACY For personal use only CHM 1101 induced complete eradication of tumours with no relapse in seven mouse xenograft tumour models Gastric Pancreatic Neuroendocrine Tumours Cancer Cancer Source: Feng et al., Nature Cancer, 2022
Slide 25: CHM 2101 for Gastrointestinal Cancers: Advancing Towards Clinic
CHM 2101 for GASTROINTESTINAL CANCERS ADVANCING TOWARDS CLINIC For personal use only PRECLINICAL PRECLINICAL VECTOR FDA TECHNICAL FDA IN VITRO IN VIVO MANUFACTURING PRE IND OPERATIONS IND STUDIES STUDIES & RELEASE MEETING READINESS CLEARANCE
Slide 26: CHM 2101 Phase 1A Clinical Trial in GI Cancers
CHM 2101 (CDH17 CAR T) PHASE 1A CLINICAL TRIAL IN RELAPSE / REFRACTORY GI CANCERS For personal use only Accelerated development through a Phase 1A basket trial design with patient eligibility in 3 tumour types Upon signal confirmation, dose confirmation and expansion in tumour specific cohorts Color
Slide 27: CHM 0201
CHM 0201 Broad Encouraging For personal use only A platform applicability Phase 1A technology across 10+ Clinical Trial that can be disease areas Results across leveraged to including blood multiple key develop cancers and endpoints in multiple new solid tumours Acute Myeloid therapies Leukemia and
Slide 28: CHM 0201 for Blood Cancers and Solid Tumours
CHM 0201 for BLOOD CANCERS AND SOLID TUMOURS ADVANCING NOVEL PHASE 1B CLINICAL COMBINATIONS For personal use only CHM 0201 CHM 0201 + VACTO CHM 0201 + AZA/VEN Phase 1A Phase 1B Phase 1B COMPLETE ONGOING ENROLLMENT ENROLLMENT LATE 2023 Established Safety Initiated January 2023 FDA IND Clearance 100%
Slide 29: Chimeric Management Team
CHIMERIC MANAGEMENT TEAM EXPERTS IN CELL THERAPY DEVELOPMENT & COMMERCIALISATION EXPERIENCE EXPERTISE PROVEN For personal use only 75+ Years of Cell Therapy 50+ Of the 4/6 Development Experience FDA-Approved Programs CAR T Cell Therapies Dr Jason Dr Eliot Kelly Cassandra Dr Stephanie LITTEN BOURK TH
Slide 30: Positive Clinical Data in GBM and AML
3 2 POSITIVE CLINICAL DATA in GBM and AML Two assets with positive Phase 1A clinical data ADVANCING CLINICAL DEVELOPMENT For personal use only Four ongoing clinical trials in solid tumours and blood cancers NEAR TERM MILESTONES Multiple clinical catalysts in next 12-18 months IMPACTFUL BUSINESS DEVE
Slide 31: Key Risks
KEY RISKS KEY SPECIFIC RISKS ASSOCIATED WITH CHIMERIC’S BUSINESS Dependence upon Chimeric is reliant on the continuing operation of its key license agreements. A failure of licensors to comply with the terms of any applicable license For personal use only Licence Agreements agreements could have a m
Slide 32: Key Risks
KEY RISKS Key specific risks associated with Chimeric’s business The Company may collaborate with pharmaceutical and life science companies, academic institutions or other partners to complete the development For personal use only Arrangements with and commercialisation of its products. If Chimeric
Chimeric Therapeutics — Investor Presentation (October 2023) on 6ix